Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Rookie Sensations
San Francisco - Accumulating evidence suggests new biologic agents may be used with potential benefit in the management of dermatomyositis, pyoderma gangrenosum, bullous diseases, cutaneous sarcoidosis, and severe atopic dermatitis.Dermatologists, however, have also been looking to use various older therapies in new ways to treat these disabling diseases, Jeffrey P. Callen, M.D., said.
Related Videos
Related Content
